Exscientia (NASDAQ:EXAI) Sets New 1-Year Low at $4.13

Shares of Exscientia plc (NASDAQ:EXAI) reached a new 52-week low on Wednesday . The company traded as low as $4.13 and last traded at $4.16, with a volume of 213422 shares. The stock had previously closed at $4.38.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Bank of America cut shares of Exscientia from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $11.00 to $9.00 in a research report on Friday, January 5th. Morgan Stanley reissued an “equal weight” rating and issued a $7.00 price objective on shares of Exscientia in a report on Monday.

Exscientia Trading Down 5.7 %

The business’s 50 day moving average price is $5.73 and its two-hundred day moving average price is $5.85. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.22. The company has a market capitalization of $499.28 million, a price-to-earnings ratio of -2.96 and a beta of 0.78.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $41.63 million. Equities analysts forecast that Exscientia plc will post -1.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after purchasing an additional 2,302 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Exscientia by 359.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after acquiring an additional 4,104 shares in the last quarter. Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of Exscientia in the fourth quarter worth approximately $64,000. Rathbones Group PLC acquired a new position in Exscientia in the 3rd quarter valued at approximately $47,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in Exscientia in the 3rd quarter worth approximately $58,000. 41.58% of the stock is owned by institutional investors and hedge funds.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.